Dr. Michael Rosenblatt joins Ferring Pharmaceuticals’ Board of Directors
- Ferring appoints Dr Michael Rosenblatt to its Board of Directors.
- Dr Rosenblatt has served as a founding scientist, scientific advisory board member, and director of several biopharmaceutical companies.
- Jan Lundberg is stepping down from his role of Chairman of the Board Research and Development and Production Committee
Saint-Prex, Switzerland – 23 July 2024 – Ferring Pharmaceuticals announced today that Dr Michael Rosenblatt joins its Board of Directors as Chairman of the Board Research and Development and Production Committee, replacing Jan Lundberg who is stepping down from his role. Over the course of his career, he has served as a founding scientist, scientific advisory board member, and director of several biopharmaceutical companies. Dr Rosenblatt joined Flagship Pioneering in 2016 as chief medical officer and has served as an advisor for its ecosystem of companies. From 1984 he spent nearly a decade at Merck, Sharpe and Dohme’s Research Laboratories where he led multiple R&D programs, returning to Merck as executive vice president and chief medical officer from 2009 to 2016.
In addition to his deep industry experience, Dr Rosenblatt held a wide range of academic appointments including, Dean of Tufts University School of Medicine; Robert H. Ebert Professor of Molecular Medicine and George R. Minot Professor of Medicine, both at Harvard Medical School; president, Harvard faculty dean and senior vice president for academic programs of Beth Israel Deaconess Medical Center; and director of the Harvard-MIT Division of Health Sciences and Technology. Dr Rosenblatt is the holder of 19 patents, is the author or co-author of over 180 peer-reviewed papers and commentaries and holds both an undergraduate degree summa cum laude from Columbia and a M.D. magna cum laude from Harvard.
Commenting on Dr Rosenblatt’s replacement of Dr. Jan Lundberg on the Ferring Board of Directors, Jean-Frédéric Paulsen, Chairman of the Board of Directors, said: “I would like to thank Dr. Lundberg for his many contributions to the Board and his partnership over the past three years. We are delighted to welcome Dr Michael Rosenblatt to the Ferring Board of Directors. This appointment resumes his long-standing relationship with our company which began more than 40 years ago. He brings a wealth of scientific knowledge, industry experience and a strong commitment to deliver real value to patients, providers, and payors.“
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.
Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
For more information, please contact
Carine Julen
Manager, Corporate Communications
+41 76 301 01 78 (mobile)
carine.julen@ferring.com
Mark Baecher
Media Relations, Life Science Communication
+41 78 601 56 08 (mobile)
mark.baecher@lscom.ch
